PM-359 is a gene-modified cell therapy commercialized by Prime Medicine, with a leading Phase II program in Chronic Granulomatous Disease. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of PM-359’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for PM-359 is expected to reach an annual total of $23 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
PM-359 Overview
PM-359 is under development for the treatment of chronic granulomatous disease (CGD). The therapeutic candidate comprises of genetically modified hematopoietic stem cells, which are modified by prime editor protein comprising a Cas nickase domain, reverse transcriptase domain, together with a prime editing guide RNA (pegRNA) delivered by a lentiviral vector. It is administered through intravenous route.
Prime Medicine Overview
Prime Medicine is a biotechnology company that develops precision genetic medicines to treat serious genetic diseases. The company’s gene editing technology, Prime Editing, is designed to edit, correct, insert and delete DNA sequences in any target tissue. Prime Medicine develops a product candidate, PM359, that targets the p47phox variant of chronic granulomatous disease. Its product portfolio of investigational therapeutic programs is organized on various therapeutic areas including hematology and immunology, liver, lung, cancers, infectious diseases, ocular and neuromuscular. Prime Medicine is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$204.8 million in FY2023, compared to an operating loss of US$116.5 million in FY2022. The net loss of the company was US$198.1 million in FY2023, compared to a net loss of US$121.8 million in FY2022.
For a complete picture of PM-359’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
